Frontlight ResearchEarly access
Taking people in United StatesPhase 2
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Chandler, Fort Worth, Miami Lakes, San Antonio, and Topeka, United StatesSee the 5 sitesAlso in 3 other countries, 8 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 274 people, planned
- Started
- 31 Aug 2026
- Expected to end
- 14 Jan 2030
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Efimosfermin alfa
- Placebo
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Participant must be 18 to 75 years of age inclusive, at the time of Screening
- Capable of giving signed informed consent prior to the performance of any study-specific procedures
- Able and willing to comply with all study assessments and adhere to the protocol schedule of activities
- History of heavy alcohol consumption for greater than 6 months at any time prior to Screening
- A female participant is eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:; Is a Participant of non-childbearing potential (PONCBP) OR; Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (<)1 percentage (%), 30 days prior to and during the study intervention period and for at least 16 weeks after the last dose of study intervention
Who cannot take part
- Any major surgery within 3 months prior to Screening 1 or planned during the study
- Prior use of a Fibroblast growth factor 21 (FGF21) analogue, including efimosfermin, within the 6 months prior to Screening 1
- Individuals with a history of resmetirom use within 3 months prior to Day 1 are to be excluded
- Concomitant use of investigational drugs for Metabolic dysfunction-associated steatohepatitis (MASH) or ALD
- Current or planned participation in any clinical trial of investigational therapies or medical devices
- Other primary causes of liver disease (e.g., viral hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, drug-induced hepatotoxicity, Wilson disease, hemochromatosis, alpha-1-antitryspin deficiency, etc.). Alcohol must be the primary cause of liver disease
- Co-infection with Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV) as indicated from the central lab
- History of diabetes mellitus (DM), either:; Type 1 DM; Type 2 DM with unstable glycemic control or with major complications
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the 3 years prior to Screening 1, regardless of any evidence of local recurrence or metastasis
- Current, or history of known hepatocellular carcinoma (HCC)
- Any surgical or medical condition that might jeopardize the individual's safety or compliance with study procedures in the opinion of the investigator
- All organ transplant recipients, except for history of corneal transplants, or current listing or active consideration for liver transplant during the Screening period
- Poorly controlled hypertension
- Evidence of Wernicke-Korsakoff syndrome or alcohol-related dementia
- History of hypersensitivity (such as anaphylaxis or hepatotoxicity) to study intervention and/or its excipients, drugs of similar biological class, FGF21 protein analogs, Fc-fusion proteins, or other protein-based therapeutics
- Exceeding pre-defined laboratory parameters for Triglycerides, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), International normalised ratio (INR), Albumin, Urine albumin-creatinine ratio (uACR) or Glycosylated Hemoglobin (HbA1c)
- History of drug abuse within the 12 months prior to Day 1 or evidence of such abuse as indicated by laboratory assays conducted at Screening
- Overt hepatic encephalopathy (West Haven grade >=2)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
Also in 3 other countries, 8 sites
- Chandler, ArizonaHospital not named in the registryContact: Anita Kohli (principal investigator)Taking people
- Fort Worth, TexasHospital not named in the registryContact: Thomas Cotter (principal investigator)Taking people
- Miami Lakes, FloridaHospital not named in the registryContact: William Sanchez (principal investigator)Taking people
- San Antonio, TexasHospital not named in the registryContact: Eric Lawitz (principal investigator)Taking people
- Topeka, KansasHospital not named in the registryContact: Shekhar Challa (principal investigator)Taking people
About the trial
What the trial wants to find out
This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.
The 4 groups in the trial
- Efimosfermin alfa Dose Level 1Treatment being tested
Participants will receive efimosfermin alfa dose level 1.
Treatment: Efimosfermin alfa
- Efimosfermin alfa Dose Level 2Treatment being tested
Participants will receive efimosfermin alfa dose level 2.
Treatment: Efimosfermin alfa
- Efimosfermin alfa Dose Level 3Treatment being tested
Participants will receive efimosfermin alfa dose level 3.
Treatment: Efimosfermin alfa
- PlaceboPlacebo, for comparison
Participants will receive placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)
- Fit questions
- Built from NCT07791043, who can take part
- Record updated
- 12 November 2026